Imidazotriazines and imidazopyrimidines as kinase inhibitors

(19)

(11)

EP 2 497 470 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.12.2015 Bulletin 2015/49

(45)	Mention of the grant of the patent:
	28.10.2015 Bulletin 2015/44

(21)	Application number: 12158715.8

(22)	Date of filing: 19.11.2007

(51)

International Patent Classification (IPC):

A61K 31/198^(2006.01)
C07D 487/04^(2006.01)

A61K 31/519^(2006.01)

(54)	Imidazotriazines and imidazopyrimidines as kinase inhibitors Imidazotriazine und Imidazopyrimidine als Kinasehemmer Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinase

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR MK RS

(30)

Priority:

22.11.2006 US 860840 P
29.11.2006 US 861459 P
22.08.2007 US 957236 P

(43)	Date of publication of application:
	12.09.2012 Bulletin 2012/37

(60)	Divisional application:
	15191241.7

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	07864592.6 / 2099447

(73)	Proprietor: Incyte Holdings Corporation
	Wilmington, DE 19803 (US)

(72)

Inventors:

Zhuo, Jincong
Boothwyn, PA Pennsylvania 19061 (US)
Metcalf, Brian
Moraga, CA California 94556 (US)
Xu, Meizhong
Hockessin, DE Delaware 19707 (US)
He, Chunhong
Boothwyn, PA Pennsylvania 19061 (US)
Zhang, Colin
Ambler, PA Pennsylvania 19002 (US)
Qian, Ding-quan
Newark, DE Delaware 19702 (US)
Burns, David M.
Philadelphia, PA Pennsylvania 19111 (US)
Li, Yunlong
Newark, DE Delaware 19711 (US)
Yao, Wenqing
Kennett Square, PA Pennsylvania 19348 (US)

(74)	Representative: Howard, Paul Nicholas
	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA London WC1B 5HA (GB)

(56)

References cited: :

WO-A-2006/124354

LABOUTA ET AL: "Potential antineoplastics: some substituted imidazo[1,2-b][1,2,4]triazines, triazino[4,3-b][1,2,4]triazines, and imidazotriazino[5,6-b]indoles", JOURNAL OF THE SERBIAN CHEMICAL SOCIETY, BELGRADE, YU, vol. 52, no. 9, 1987, pages 523-527, XP009097490, ISSN: 0352-5139

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).